The GLP-1 Pill Reports Hair Loss in 7% of Women and 0.9% of Men

The short version

The first true GLP-1 pill is real and prescribable. Orforglipron, sold as Foundayo, was approved on 1 April 2026 under application NDA 220934². It is a once-daily tablet taken with or without food, swallowed whole, with none of the fasting ritual the semaglutide tablet requires¹.

Most coverage of it stops at the weight-loss number. Its label contains three things that matter more to a woman deciding whether to take it, and none of them are in the headlines: an adverse reaction the label breaks out by sex, a contraception instruction that repeats six times, and a maximum dose that is not the dose you have been reading about.

This is educational only, not medical advice.

Hair loss, and how to read the number

The label reports hair loss separately for women and men. Pooling its two weight-reduction trials, hair loss was reported in 7% of female patients and 0.9% of male patients taking Foundayo, against 3% of female and 0.7% of male patients taking placebo¹.

The comparison that gets repeated online is 7% against 0.9% — women versus men on the drug. That comparison is wrong, because a share of it is background. Set each group against its own placebo arm instead and the picture is sharper, not softer:

Women reported hair loss more than men on placebo too, so some of the gap is not the drug at all. What the drug adds is concentrated almost entirely in women: roughly four percentage points in female patients against roughly two-tenths of a point in male patients.

Then the part that should change how you hear it. The label states plainly that hair loss adverse reactions in Foundayo-treated patients were associated with weight reduction¹. That is the label pointing at the weight loss rather than at the molecule — the shedding that follows rapid weight change in general, not a poison in the tablet. It is temporary in most people and it is not a reason on its own to refuse the drug. It is a reason to know it is coming, and to be unsurprised in month three.

The contraception instruction, and the arithmetic nobody has done

If you take an oral contraceptive, this is the section to read twice.

The label instructs women on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting Foundayo, and for 30 days after each dose escalation. Hormonal contraceptives that are not taken by mouth are not expected to be affected¹.

Now count the escalations. The starting dose is 0.8 mg. It rises to 2.5 mg after at least 30 days, then to 5.5 mg after at least another 30, and may then go to 9 mg, 14.5 mg and a maximum of 17.2 mg, each after at least 30 days on the dose below¹.

That is one initiation plus five escalations — six separate 30-day windows. And because the minimum interval between escalations is itself 30 days, at the fastest labeled titration those windows do not have gaps between them. Start on day one, step up on days 30, 60, 90, 120 and 150, and you are inside a backup-contraception window continuously from your first tablet until roughly day 180.

Six months of continuous backup is not how "add a barrier method for 30 days" sounds when you read it once. The label does not do this arithmetic for you; it falls out of putting two sections side by side. If you are on the pill and not planning a pregnancy, that is the single most consequential sentence in the document, and it deserves a specific conversation rather than a nod.

This is the same instruction tirzepatide carries³, so the pill did not inherit a gentler rule by being a pill. The full birth control comparison covers which molecules carry it and which do not.

The dose on the bottle is not the dose in the headlines

Foundayo's label describes three dose arms in its pivotal 72-week trial of 3,127 adults: 5.5 mg, 9 mg and 17.2 mg. The maximum dose that can be prescribed is 17.2 mg once daily¹.

Published coverage of the pivotal trial — the same 3,127 patients over the same 72 weeks — names the arms 6 mg, 12 mg and 36 mg. Whatever accounts for that difference, the string "36 mg" appears nowhere in the approved label, which was checked as a count across the whole document rather than assumed.

The practical consequence is small but real: if you are comparing this pill against an injectable using a "36 mg" figure, you are comparing against a number that will not appear on your prescription. Use the label's doses.

What else the label says about women specifically

Pregnancy. May cause fetal harm; discontinue when a pregnancy is recognized. There is a pregnancy exposure registry that monitors outcomes in women exposed during pregnancy¹.

Nursing. Foundayo is not recommended for nursing women¹.

Trying to conceive. Nothing in the label supports use while trying, and the contraception instruction points the other way — see trying to conceive on a GLP-1.

Combining. Concomitant use with another GLP-1 receptor agonist is not recommended¹. This is a switch, not an addition.

Where this sits on the evidence scale

The hair-loss and contraception findings are as solid as anything in this field gets: both come from an FDA-reviewed label rather than a study summary, and the adverse reaction rates come from pooled trials with a placebo comparator attached to every figure. The pivotal trial enrolled 3,127 adults, ran 72 weeks, and was 64% female — a better sex balance than most of the research this class was built on.

Two limits are worth naming. The label states that the effect of Foundayo on the absorption of oral contraceptives has not been evaluated in a clinical trial — the instruction is precautionary, derived from how the drug slows the stomach, not from a study that measured a contraceptive failing. And no data exist for pregnant or nursing women, because those trials are not run. So the six-month backup window rests on caution rather than on measurement, which is an argument for following it, not for discounting it.

For the wider picture of where this pill sits against the injectables and what is still in testing, the next-generation GLP-1 rundown carries the efficacy figures with every placebo arm attached.